GALT

Galectin Therapeutics Inc.

2.68 USD
+0.06 (+2.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Galectin Therapeutics Inc. stock is down -17.03% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 61.54% of the previous 13 June’s closed higher than May.

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc. engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer. Belapectins is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis.